Document is current
Any future updates will be listed below
-
Authors
Ho, Cindy N. https://orcid.org/0009-0008-3067-1004
Tian, Tiffany https://orcid.org/0009-0003-1417-6445
Ayers, Alessandra T. https://orcid.org/0009-0000-3054-3207
Aaron, Rachel E. https://orcid.org/0009-0005-5120-2264
Phillips, Vidith https://orcid.org/0009-0006-3832-0634
Wolf, Risa M. https://orcid.org/0000-0001-7674-520X
Mathioudakis, Nestoras https://orcid.org/0000-0002-0210-655X
Dai, Tinglong https://orcid.org/0000-0001-9248-5153
Klonoff, David C. https://orcid.org/0000-0001-6394-6862
- License Information
-
More Information
Article History
Received: 6 June 2024
Accepted: 8 November 2024
First Online: 26 November 2024
Declarations
:
: Not applicable.
: Not applicable.
: CNH and ATA are consultants for Liom. TT and REA are consultants for Clinical ink. RMW reports receiving research support from Novo Nordisk outside the submitted work. DCK is a consultant for Afon, Lifecare, Novo, Samsung, embecta, Glucotrack, SynchNeuro, and Thirdwayv. VP, NM, and TD have nothing to disclose.
